Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ATGAM safely and effectively. See full prescribing information for ATGAM. ATGAM® (lymphocyte immune globulin, anti-thymocyte globulin [equine]), sterile solution, for intravenous use onlyInitial U.S. Approval: 1981
Medication labelWhy this: Advisory · dailymed-other
ATGAM is indicated for the management of allograft rejection in renal transplant patients; when administered with conventional therapy at the time of rejection ATGAM increases the frequency of resolution of the acute rejection episode [see Clinical Studies (14.1)]. ATGAM is indicated for the treatment of moderate to severe aplastic anemia in patients unsuitable for bone marrow transplantation [see Clinical Studies (14.2)]. The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.
- generic_name
- equine thymocyte immune globulin
- product_names
- EQUINE THYMOCYTE IMMUNE GLOBULIN
- ndc
- 0009-7224, 0009-7224-01, 0009-7224-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en